Maat Pharma SA Total Liabilities
Maat Pharma SA total liabilities. Based on the latest financial reports, Maat Pharma SA (MAAT) has total liabilities worth €40.58 Million EUR (≈ $47.45 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MAAT financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Maat Pharma SA (2017–2024)
Total liabilities of Maat Pharma SA from 2017 to 2024. This chart illustrates how Maat Pharma SA's total liabilities have evolved over time, based on quarterly financial data.
Maat Pharma SA Competitors by Total Liabilities
The table below lists competitors of Maat Pharma SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Damsan JSC
VN:ADS
|
Vietnam | ₫1.57 Trillion |
|
Idomoo Ltd
TA:IDMO
|
Israel | ILA19.38 Million |
|
Brookside Energy Limited
F:8F3
|
Germany | €22.08 Million |
|
K2A Knaust & Andersson Fastigheter AB (publ)
ST:K2A-PREF
|
Sweden | Skr4.87 Billion |
|
Evergreen Fibreboard Bhd
KLSE:5101
|
Malaysia | RM385.43 Million |
|
NeuPath Health Inc
V:NPTH
|
Canada | CA$23.16 Million |
|
Greenidge Generation Holdings Inc
NASDAQ:GREE
|
USA | $99.97 Million |
|
Talam Transform Bhd
KLSE:2259
|
Malaysia | RM379.74 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Maat Pharma SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Maat Pharma SA assets under control.
Liquidity & Leverage Metrics
Maat Pharma SA Total Liabilities Ratios Explained
Maat Pharma SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.83 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Maat Pharma SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Maat Pharma SA (2017–2024)
The table below shows the annual total liabilities of Maat Pharma SA from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €28.16 Million ≈ $32.93 Million |
+25.37% |
| 2023-12-31 | €22.46 Million ≈ $26.26 Million |
+25.40% |
| 2022-12-31 | €17.91 Million ≈ $20.94 Million |
+87.32% |
| 2021-12-31 | €9.56 Million ≈ $11.18 Million |
+14.69% |
| 2020-12-31 | €8.34 Million ≈ $9.75 Million |
-34.52% |
| 2019-12-31 | €12.73 Million ≈ $14.89 Million |
+175.89% |
| 2018-12-31 | €4.62 Million ≈ $5.40 Million |
+15.57% |
| 2017-12-31 | €3.99 Million ≈ $4.67 Million |
-- |
About Maat Pharma SA
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improve… Read more